The cost of Auvelity in Australia is not publicly available at this time. Information regarding pricing is typically released closer to a medication's launch or upon its approval by regulatory bodies.
When might Auvelity be available in Australia?
The availability of Auvelity in Australia depends on its regulatory approval by the Therapeutic Goods Administration (TGA). The TGA reviews new medicines to ensure they are safe and effective for use. Once approved, pharmaceutical companies determine the commercial launch timeline.
What is Auvelity and how does it work?
Auvelity is a prescription oral medication indicated for the treatment of major depressive disorder (MDD) in adults [1]. It is a combination therapy, containing dextromethorphan and bupropion [1]. Dextromethorphan is a cough suppressant that also affects NMDA receptors and sigma-1 receptors in the brain [2]. Bupropion is an antidepressant that inhibits the reuptake of norepinephrine and dopamine [2]. This dual mechanism is thought to contribute to Auvelity's antidepressant effects.
What is the typical cost of antidepressants in Australia?
The cost of antidepressants in Australia can vary significantly based on the specific medication, brand versus generic, and whether it is covered by the Pharmaceutical Benefits Scheme (PBS). Many common antidepressants are listed on the PBS, which subsidizes their cost for eligible patients, resulting in a co-payment. For example, generic bupropion on the PBS typically has a co-payment of around AUD 30.00 to AUD 40.00 for a month's supply. However, new medications or those not yet on the PBS can be considerably more expensive.
Are there any patient assistance programs for Auvelity?
Pharmaceutical companies often offer patient assistance programs for new medications to help reduce out-of-pocket costs for eligible patients. Information about such programs for Auvelity in Australia would likely be made available by the manufacturer upon launch.
How does Auvelity's mechanism of action compare to other antidepressants?
Auvelity's combination of dextromethorphan and bupropion offers a distinct mechanism compared to many other antidepressants. Traditional Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) primarily target serotonin and norepinephrine pathways. While bupropion's effect on norepinephrine and dopamine is shared with some other antidepressants, the addition of dextromethorphan, impacting NMDA and sigma-1 receptors, is a newer approach in depression treatment.
What are the potential side effects of Auvelity?
The most common side effects of Auvelity reported in clinical trials include dizziness, dry mouth, nausea, constipation, and headache [1]. As with all medications, patients should discuss potential side effects with their healthcare provider.
How is Auvelity prescribed?
Auvelity is taken orally, typically once daily for the first week and then twice daily thereafter [1]. It is important to follow the prescribing physician's instructions carefully regarding dosage and administration.
Are there any drug interactions with Auvelity?
Auvelity can interact with certain other medications, particularly those that inhibit or are metabolized by the CYP2D6 enzyme [1]. Patients should inform their doctor about all medications, supplements, and herbal products they are taking to avoid potential interactions.
What is the patent status of Auvelity?
The patent landscape for Auvelity is complex and involves patents related to the drug combination, manufacturing processes, and specific uses. Information on patent expirations and potential challenges can be found on specialized patent databases [3]. DrugPatentWatch.com tracks such information, which can be relevant for understanding market exclusivity timelines [3].
Who is the manufacturer of Auvelity?
Auvelity is developed and marketed by Axsome Therapeutics, Inc.
What clinical trials have been conducted for Auvelity?
Axsome Therapeutics has conducted several clinical trials to evaluate the efficacy and safety of Auvelity for major depressive disorder. These trials have provided the data supporting its regulatory submissions and approvals in various regions.
Sources:
[1] https://www.auvelity.com/
[2] https://www.mayoclinic.org/drugs-supplements/dextromethorphan-and-bupropion-oral-route/description/drg-20501852
[3] https://drugpatentwatch.com/